These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 8306107

  • 1. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
    Brownlie RP, Brownrigg NJ, Butcher HM, Garcia R, Jessup R, Lee VJ, Tunstall S, Wayne MG.
    Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
    [Abstract] [Full Text] [Related]

  • 2. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
    Brownlie RP, Brownrigg NJ, Butcher HM, Garcia R, Jessup R, Lee VJ, Tunstall S, Wayne MG.
    J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
    [Abstract] [Full Text] [Related]

  • 3. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS, Wharton KA, White BP, Lumley P.
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM, Wu TS, Teng CM.
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [Abstract] [Full Text] [Related]

  • 5. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
    Lumley P, White BP, Humphrey PP.
    Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
    [Abstract] [Full Text] [Related]

  • 6. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
    Tymkewycz PM, Jones RL, Wilson NH, Marr CG.
    Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J, Rolin S, Reynaud D, Qiao N, Kelley LP, Reid HM, Valentin F, Tippins J, Kinsella BT, Masereel B, Pace-Asciak C, Pirotte B, Dogné JM.
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [Abstract] [Full Text] [Related]

  • 8. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
    Chang TS, Kim HM, Lee KS, Khil LY, Mar WC, Ryu CK, Moon CK.
    Biochem Pharmacol; 1997 Jul 15; 54(2):259-68. PubMed ID: 9271330
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F, Colombo M, Pierucci L, Volpi D, Dho L, Ukmar G, Rosa B, Salvati P.
    Drugs Exp Clin Res; 1993 Jul 15; 19(6):249-60. PubMed ID: 8013268
    [Abstract] [Full Text] [Related]

  • 10. A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors.
    Ackerley N, Brewster AG, Brown GR, Clarke DS, Foubister AJ, Griffin SJ, Hudson JA, Smithers MJ, Whittamore PR.
    J Med Chem; 1995 May 12; 38(10):1608-28. PubMed ID: 7752186
    [Abstract] [Full Text] [Related]

  • 11. Antagonism of prostaglandin-mediated responses in platelets and vascular smooth muscle by 13-azaprostanoic acid analogs. Evidence for selective blockade of thromboxane A2 responses.
    Huzoor-Akbar, Mukhopadhyay A, Anderson KS, Navran SS, Romstedt K, Miller DD, Feller DR.
    Biochem Pharmacol; 1985 Mar 01; 34(5):641-7. PubMed ID: 3156599
    [Abstract] [Full Text] [Related]

  • 12. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C, Beetens JR, Tegtmeier F, Van Rooy P, Vercammen E, Wouters L, De Clerck F.
    Thromb Haemost; 1992 Aug 03; 68(2):214-20. PubMed ID: 1412169
    [Abstract] [Full Text] [Related]

  • 13. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
    Cozzi P, Giordani A, Menichincheri M, Pillan A, Pinciroli V, Rossi A, Tonani R, Volpi D, Tamburin M, Ferrario R.
    J Med Chem; 1994 Oct 14; 37(21):3588-604. PubMed ID: 7932586
    [Abstract] [Full Text] [Related]

  • 14. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F, Beetens J, de Chaffoy de Courcelles D, Freyne E, Janssen PA.
    Thromb Haemost; 1989 Feb 28; 61(1):35-42. PubMed ID: 2546278
    [Abstract] [Full Text] [Related]

  • 15. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
    Tubaro E, Belogi L, Mezzadri CM.
    Arzneimittelforschung; 1996 Jan 28; 46(1):35-41. PubMed ID: 8821515
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological actions of ICI 180080, a novel thromboxane receptor antagonist.
    Jessup CL, Jessup R, Wayne M.
    J Pharm Pharmacol; 1986 Oct 28; 38(10):754-7. PubMed ID: 2878996
    [Abstract] [Full Text] [Related]

  • 17. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
    Greenberg SS, Johns A, Kleha J, Xie J, Wang Y, Bianchi J, Conley K.
    J Pharmacol Exp Ther; 1994 Mar 28; 268(3):1352-61. PubMed ID: 8138950
    [Abstract] [Full Text] [Related]

  • 18. Redirection of arachidonic acid metabolism by ICI D1542: effects on thrombus formation in the coronary artery of the anaesthetized dog.
    McAuliffe SJ, Moors JA, Snow HM, Wayne M, Jessup R.
    Br J Pharmacol; 1993 Apr 28; 108(4):901-6. PubMed ID: 8485629
    [Abstract] [Full Text] [Related]

  • 19. 6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.
    Soyka R, Heckel A, Nickl J, Eisert W, Müller TH, Weisenberger H.
    J Med Chem; 1994 Jan 07; 37(1):26-39. PubMed ID: 8289199
    [Abstract] [Full Text] [Related]

  • 20. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P, Ambrosio G, Villari B, Ragni M, Focaccio A, Pace L, de Clerk F, Condorelli M, Chiariello M.
    J Am Coll Cardiol; 1993 Feb 07; 21(2):493-501. PubMed ID: 8426016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.